RAC1 is a member of the Rho GTPase subfamily within the RAS superfamily, regulating the actin cytoskeleton architecture, cell spreading, migration and proliferation. De novo missense variants in RAC1 underlie a spectrum of syndromic conditions characterized by developmental delay/intellectual disability (DD/ID), brain abnormalities, and variable multisystem involvement. Given the extensive crosstalk between RAC1-mediated pathways and the RAS-MAPK signaling cascade, dysregulation of this signaling axis may contribute to the pathogenesis of RAC1-associated disorders. Here, we describe a familial case characterized by a previously unreported heterozygous RAC1 missense change (c.38C>A, p. A13D). Affected mother and son presented with DD/ID and facial features, suggestive of Noonan syndrome. To functionally characterize the variant, we assessed RAC1 levels and activity, MAPK activation and cell spreading in patient-derived primary fibroblasts and cells transiently overexpressing either WT or mutant RAC1 proteins. We demonstrate a gain-of-function behavior of the variant, resulting in increased RAC1 activity, and enhanced cell spreading. In addition to cytoskeletal reorganization, variant expression triggered significant hyperactivation of MAPK signaling, supporting a contribution to the RASopathy-like features of the affected individuals. Interestingly, the SHP2 inhibitor SHP099 abrogated ERK hyperactivation induced by RAC1 variant, suggesting a critical role for this phosphatase in the underlying pathogenic mechanism. To determine whether additional RAC1 variants share molecular and clinical hallmarks with RASopathies, we biochemically characterized a panel of pathogenic missense changes and compared the associated phenotypes. Consistent with the marked clinical heterogeneity of RAC1-related disorders, several variants (p.C18Y, p.Y32H, p.V51M, and p.A159T) shared a subset of phenotypic characteristics occurring in RASopathies, and increased ERK signaling. In contrast, variants affecting the N-terminal region of the Switch II domain (p.E62K and p.Y64D) showed neither significant RAS-MAPK dysregulation nor prominent RASopathy-associated features. Overall, this study functionally characterizes a novel RAC1 pathogenic variant causing RAS-MAPK hyperactivation and a Noonan syndrome-like phenotype. Our findings suggest that RASopathy-related traits may represent part of the broader phenotypic spectrum of RAC1-NDD disorders due to aberrant RAS-MAPK signaling induced by a subset of RAC1 variants. These results also support the inclusion of RAC1 in diagnostic gene panels for RASopathies to facilitate the differential diagnosis of cases displaying partial phenotypic overlap.

The Ala13Asp substitution in RAC1 enhances MAPK signaling and dysregulates cytoskeletal function, causing a neurodevelopmental condition with features resembling Noonan syndrome / Barone, M.C., Leenders, E., Ronco, A.B.P., Motta, M., Spadaro, F., Rinne, T., Draaisma, J., Zara, E., Ferruti, E., Priolo, M., Tartaglia, M., Coppola, S.. - (2026). (10th International Meeting on Rare Disorders of the RAS-MAPK Pathway Roma ).

The Ala13Asp substitution in RAC1 enhances MAPK signaling and dysregulates cytoskeletal function, causing a neurodevelopmental condition with features resembling Noonan syndrome

M. C. Barone;A. B. P. Ronco;
2026

Abstract

RAC1 is a member of the Rho GTPase subfamily within the RAS superfamily, regulating the actin cytoskeleton architecture, cell spreading, migration and proliferation. De novo missense variants in RAC1 underlie a spectrum of syndromic conditions characterized by developmental delay/intellectual disability (DD/ID), brain abnormalities, and variable multisystem involvement. Given the extensive crosstalk between RAC1-mediated pathways and the RAS-MAPK signaling cascade, dysregulation of this signaling axis may contribute to the pathogenesis of RAC1-associated disorders. Here, we describe a familial case characterized by a previously unreported heterozygous RAC1 missense change (c.38C>A, p. A13D). Affected mother and son presented with DD/ID and facial features, suggestive of Noonan syndrome. To functionally characterize the variant, we assessed RAC1 levels and activity, MAPK activation and cell spreading in patient-derived primary fibroblasts and cells transiently overexpressing either WT or mutant RAC1 proteins. We demonstrate a gain-of-function behavior of the variant, resulting in increased RAC1 activity, and enhanced cell spreading. In addition to cytoskeletal reorganization, variant expression triggered significant hyperactivation of MAPK signaling, supporting a contribution to the RASopathy-like features of the affected individuals. Interestingly, the SHP2 inhibitor SHP099 abrogated ERK hyperactivation induced by RAC1 variant, suggesting a critical role for this phosphatase in the underlying pathogenic mechanism. To determine whether additional RAC1 variants share molecular and clinical hallmarks with RASopathies, we biochemically characterized a panel of pathogenic missense changes and compared the associated phenotypes. Consistent with the marked clinical heterogeneity of RAC1-related disorders, several variants (p.C18Y, p.Y32H, p.V51M, and p.A159T) shared a subset of phenotypic characteristics occurring in RASopathies, and increased ERK signaling. In contrast, variants affecting the N-terminal region of the Switch II domain (p.E62K and p.Y64D) showed neither significant RAS-MAPK dysregulation nor prominent RASopathy-associated features. Overall, this study functionally characterizes a novel RAC1 pathogenic variant causing RAS-MAPK hyperactivation and a Noonan syndrome-like phenotype. Our findings suggest that RASopathy-related traits may represent part of the broader phenotypic spectrum of RAC1-NDD disorders due to aberrant RAS-MAPK signaling induced by a subset of RAC1 variants. These results also support the inclusion of RAC1 in diagnostic gene panels for RASopathies to facilitate the differential diagnosis of cases displaying partial phenotypic overlap.
2026
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1779324
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact